StreetAlpha.app
Home › Stocks › PCVX

Vaxcyte, Inc. (PCVX)

Healthcare
$59.46
▼ −3.49%
LAST CLOSE · NOV 17

Vaxcyte is developing pneumococcal vaccines for adults and children, made with its XpressCF protein production platform. It last closed at $59.46 on Nov 17, down 3.49% on the day. The average 12-month price target from 4 analysts is $124.25 (+109.0% from the last close), with a high of $130.00 and a low of $120.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in PCVX, 0% of them bullish and 100% bearish. In the past 30 days there were 4 dark pool prints totaling $2.9M, the largest $910K.

AI Auto Pilots
Is PCVX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$1.1B
EPS (diluted)
−$8.05
Free cash flow
−$974.4M
Valuation
Market cap
$9.4B
158.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$125.5M
At Sep 30
Shareholder equity
$2.5B
Shares outstanding
158.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$100.1M−$100.1MFY2021FY2022: −$223.5M−$223.5MFY2022FY2023: −$402.3M−$402.3MFY2023FY2024: −$463.9M−$463.9MFY2024FY2025: −$766.6M−$766.6MFY2025

From PCVX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on PCVX in the past 90 days
Average 12-month target
$124.25
▲ 109.0% upside

Based on 4 analysts who set a price target on PCVX in the past 90 days. The average target is $124.25, with a high of $130.00 and a low of $120.00, compared with the last close of $59.46.

Low $120.00Avg $124.25High $130.00
Blue marker: last close $59.46
Highest target$130.00
Average target$124.25
Lowest target$120.00
Latest rating changes
Cantor FitzgeraldReiterated
Oct 12Buy$120
NeedhamMaintained
Oct 5Buy$122
GuggenheimMaintained
Oct 5Buy$125
B of A SecuritiesMaintained
Sep 28Buy$130
DateFirmActionRatingPrice target
Oct 12Cantor FitzgeraldReiteratedBuy$120
Oct 5NeedhamMaintainedBuy$122
Oct 5GuggenheimMaintainedBuy$125
Sep 28B of A SecuritiesMaintainedBuy$130
Loading…

Technical Analysis

PCVX · as of the Nov 17 close · updated after every close
Pullback inside a longer uptrend

The stock is 6% below its 20 day and 5% below its 50 day average. It is 3% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 43). The nearest support is the swing low (Oct 26) at $59.19, and the nearest resistance the swing high (Jun 30) at $59.50.

Short trendBearish
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 5.6%/day
Key levels
$90.7552 week high+52.6%
$62.8920 day average+5.8%
$62.2350 day average+4.7%
$61.68Pivot R1+3.7%
$60.37Pivot+1.5%
$60.25100 day average+1.3%
$59.50Swing high (Jun 30)+0.1%
$59.46Last close
$59.19Swing low (Oct 26)−0.5%
$58.16Pivot S1−2.2%
$57.75200 day average−2.9%
$42.4052 week low−28.7%
Indicators
RSI (14)43.09Middle of its rangeNeutral
MACD0.07Below its signal lineBearish
Stochastic22.4Middle of its rangeNeutral
ADX (14)23.7Weak trend
Williams %R-96.0Oversold below −80, overbought above −20Oversold
CCI (20)-100.9Oversold below −100, overbought above 100Oversold
Rate of change−2.2%Change over 10 sessionsBearish
ATR (14)$3.32Typical daily range, 5.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Above
What happened before, for PCVX

What happened before

See how PCVX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PCVX usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PCVX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
0
0%
Bearish
1
100%
Date span
Oct 5 – Oct 5
Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
4
Notional
$2.9M
Largest print
$910K
Loading…

PCVX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲196 buying vs 143 selling
  • ▲Held by funds +1.5 pts
  • ▲Funds holding +22
  • ▼Superinvestors: 1 added, 3 cut
  • ▲Put/call 2.09 to 1.63
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding357335+6.6%
In funds' top 101014−28.6%
Held by funds107.4%105.9%+1.5 pts
New / increased65 / 13147 / 132+9.5%
Reduced / sold out101 / 42100 / 51−5.3%
Put/call ratio1.632.09−22.2%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PCVX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PCVX is in one of them and how their past PCVX trades turned out.

PCVX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PCVX in an article yet. Here's the latest on the wider market.

PCVX Congress Trades

All congress trades →
Trades, 12 months
3
Buys
3
100%
Sells
0
0%
People
1
Last filed Sep 4
Who traded PCVX · since 2022
Latest 5 filings of 13
$1K – $15KTraded Jul 16, 2026Filed Sep 4, 2026
$1K – $15KTraded May 13, 2026Filed Jun 8, 2026
$1K – $15KTraded May 12, 2026Filed Jun 8, 2026
$1K – $15KTraded Feb 11, 2025Filed May 14, 2025
$1K – $15KTraded Apr 28, 2025Filed May 7, 2025
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KJul 16, 2026Sep 4, 202650 d
Gilbert CisnerosD · CABuy$1K – $15KMay 13, 2026Jun 8, 202626 d
Gilbert CisnerosD · CABuy$1K – $15KMay 12, 2026Jun 8, 202627 d
Sean DuffyExecutive branchSell$1K – $15KFeb 11, 2025May 14, 202592 d
Gilbert CisnerosD · CABuy$1K – $15KApr 28, 2025May 7, 20259 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Vaxcyte

Vaxcyte is a biotechnology company based in San Carlos, California, that is developing vaccines to protect against bacterial diseases. Its main focus is pneumococcal vaccines, which guard against infections caused by Streptococcus pneumoniae bacteria, including pneumonia and meningitis. The company uses XpressCF, a protein production platform that does not rely on living cells, to make these complex vaccines. Its candidates are still in clinical trials for adults and infants, so they are not yet sold.

Headquarters
San Carlos, CA